RAPT Therapeutics, Inc. (RAPT)
NASDAQ: RAPT · Real-Time Price · USD
29.44
+0.42 (1.45%)
At close: Oct 8, 2025, 4:00 PM EDT
29.44
0.00 (0.00%)
After-hours: Oct 8, 2025, 4:00 PM EDT
RAPT Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
68
Market Cap
488.69M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | - | - | - |
Dec 31, 2023 | - | - | - |
Dec 31, 2022 | 1.53M | -2.29M | -59.95% |
Dec 31, 2021 | 3.81M | -1.23M | -24.38% |
Dec 31, 2020 | 5.04M | - | - |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
RAPT News
- 9 days ago - RAPT Therapeutics Announces FDA Clearance of IND Application to Proceed to Phase 2b Trial of RPT904 in Food Allergy - GlobeNewsWire
- 6 weeks ago - RAPT Therapeutics to Participate in Multiple Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - RAPT Therapeutics Reports Second Quarter 2025 Financial Results - GlobeNewsWire
- 3 months ago - RAPT Therapeutics Names Two Industry Veterans to its Board of Directors - GlobeNewsWire
- 4 months ago - RAPT Therapeutics Announces Effective Date for 1-for-8 Reverse Stock Split - GlobeNewsWire
- 4 months ago - RAPT Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 5 months ago - RAPT Therapeutics Reports First Quarter 2025 Financial Results - GlobeNewsWire
- 6 months ago - RAPT Therapeutics Deepens Expertise in Allergic Diseases with Appointment of Jessica Savage, M.D., M.H.S., as Vice President, Clinical Development - GlobeNewsWire